GreenLight SPAC Presentation Deck

GreenLight's vision to enable a global RNA manufacturing network Globally distributed units can address vaccine nationalism, adapt to variants, and offer non-pandemic advanced therapies RESEARCH LAB W 1. FILL & FINISH VACCINE PRODUCTION DATEN E org COVID SICKLE LESE FLU g COVID SICKLE CELL DISEASE FLU ********* DOMESTIC COVID CLE LL ASE U EXPORT Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Our vision is to enable the Africa, Asia, and Latin America regions to meet local demand through local production. A global mRNA vaccine manufacturing network could dramatically increase vaccine supplies, eliminate vaccine nationalism, respond quickly to variants, and offer non- pandemic RNA manufacturing for other indications. The network is planned to be distributed and interoperable, each facility will have less reliance on international supply chains to create vaccines for locally prevalent strains while being able to offer support for other facilities should need arise. GreenLight looks to deploy its proprietary RNA manufacturing process locally using modular design concepts that can constructed off-site and set up quickly in country. The facilities will be locally operated by a team of fewer than 100 staff to produce 1 billion vaccination courses per year. HUMAN HEALTH 28

View entire presentation